uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-20-240-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.28 million
Profitability
Miscellaneous
Employees212
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) issued its earnings results on Monday, July, 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.08. The biotechnology company had revenue of $2.47 million for the quarter, compared to analysts' expectations of $1.53 million. Uniqure had a negative return on equity of 61.67% and a negative net margin of 1,232.30%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
11 brokers have issued 12-month price targets for Uniqure's stock. Their forecasts range from $35.00 to $100.00. On average, they expect Uniqure's share price to reach $78.10 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (8/2/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $81 PT on uniQure. This morning, Spark (Neutral) filed a 14D-9, which detailed a timeline (Figure 1) of potential partnership and acquisition talks the company had. Our key takeaway is that four parties, including Roche (RHHBY – NC) were in discussions regarding a co- development and co-promotion partnership relating to hemophilia A. Three of these parties (including Roche) were involved in acquisition talks. This detailed process indicates there is an immense interest in hemophilia gene therapy programs from pharma." (3/7/2019)
- 3. HC Wainwright analysts commented, "Our $73 price target, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single- arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during 2H21, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $765M, during 2028. We assume a launch price of $850K, which could be an underestimate based on the 7 plus years of anticipated durability." (2/26/2019)
Has Uniqure been receiving favorable news coverage?
News headlines about QURE stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Uniqure earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Uniqure.
Are investors shorting Uniqure?
Uniqure saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 3,066,900 shares, an increase of 6.1% from the June 30th total of 2,890,400 shares. Based on an average daily trading volume, of 748,200 shares, the short-interest ratio is currently 4.1 days. Approximately 14.6% of the shares of the company are sold short. View Uniqure's Current Options Chain.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC) and FibroGen (FGEN).
What other stocks do shareholders of Uniqure own?
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
- Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operations Officer (Age 60)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by a number of of institutional and retail investors. Top institutional investors include Invesco Ltd. (5.35%), Orbimed Advisors LLC (2.37%), Boxer Capital LLC (1.63%), BlackRock Inc. (1.34%), Senator Investment Group LP (1.25%) and Price T Rowe Associates Inc. MD (0.91%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Trexquant Investment LP, Senvest Management LLC, Alps Advisors Inc., Morgan Stanley, Virtus ETF Advisers LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. and Envestnet Asset Management Inc.. Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Matthew C Kapusta, Philip Astley-Sparke and Scott T Mcmillan. View Insider Buying and Selling for Uniqure.
Which institutional investors are buying Uniqure stock?
QURE stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Orbimed Advisors LLC, Senator Investment Group LP, Point72 Asset Management L.P., UBS Asset Management Americas Inc., Marshall Wace LLP, Farallon Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $56.90.
How big of a company is Uniqure?
Uniqure has a market capitalization of $2.15 billion and generates $11.28 million in revenue each year. The biotechnology company earns $-83,300,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Uniqure employs 212 workers across the globe.View Additional Information About Uniqure.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
